- Home
- RERE vs TBPH Comparison
RERE vs TBPH Comparison
Compare RERE & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- TBPH
- Stock Information
- Founded
- RERE 2011
- TBPH 2013
- Country
- RERE China
- TBPH United States
- Employees
- RERE N/A
- TBPH N/A
- Industry
- RERE Other Specialty Stores
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- RERE Consumer Discretionary
- TBPH Health Care
- Exchange
- RERE Nasdaq
- TBPH Nasdaq
- Market Cap
- RERE 580.9M
- TBPH 485.8M
- IPO Year
- RERE 2021
- TBPH N/A
- Fundamental
- Price
- RERE $2.65
- TBPH $8.58
- Analyst Decision
- RERE
- TBPH Buy
- Analyst Count
- RERE 0
- TBPH 4
- Target Price
- RERE N/A
- TBPH $13.75
- AVG Volume (30 Days)
- RERE 810.5K
- TBPH 166.7K
- Earning Date
- RERE 03-11-2025
- TBPH 02-24-2025
- Dividend Yield
- RERE N/A
- TBPH N/A
- EPS Growth
- RERE N/A
- TBPH N/A
- EPS
- RERE N/A
- TBPH N/A
- Revenue
- RERE $2,188,701,829.00
- TBPH $63,192,000.00
- Revenue This Year
- RERE $28.08
- TBPH $11.41
- Revenue Next Year
- RERE $25.05
- TBPH $37.36
- P/E Ratio
- RERE N/A
- TBPH N/A
- Revenue Growth
- RERE 27.16
- TBPH 15.93
- 52 Week Low
- RERE $1.01
- TBPH $7.44
- 52 Week High
- RERE $3.70
- TBPH $10.44
- Technical
- Relative Strength Index (RSI)
- RERE 45.31
- TBPH 33.59
- Support Level
- RERE $2.57
- TBPH $8.35
- Resistance Level
- RERE $2.69
- TBPH $8.86
- Average True Range (ATR)
- RERE 0.14
- TBPH 0.28
- MACD
- RERE -0.02
- TBPH -0.11
- Stochastic Oscillator
- RERE 34.62
- TBPH 14.74
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).